Tuesday, March 04, 2025 | 10:22 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

GST transition drags Alembic Pharma net by 36% to Rs 65 cr in June quarter

The drop is primarily on account of a transitional provisioning for GST

Alembic Pharma's Q1 net drops 36% to Rs 65 crore on transition to GST
Premium

BS Reporter Ahmedabad
Vadodara-based Alembic Pharmaceuticals posted a 36 per cent drop in net profits to Rs 65 crore in the June quarter of financial year (FY) 2017-18, as against Rs 102 crore in the corresponding period of the previous financial year. The fall in profits happened because of transition to the goods and services tax (GST) regime.

Its revenues dropped by 12 per cent year-on-year (y-o-y). Alembic posted net sales for the quarter at Rs 648 crore against Rs 737 crore in the year-ago period.
Managing Director Pranav Amin said, "The performance in the quarter was weak primarily due to the transitional

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in